D. Rea

501 total citations
22 papers, 321 citations indexed

About

D. Rea is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, D. Rea has authored 22 papers receiving a total of 321 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Cancer Research and 6 papers in Genetics. Recurrent topics in D. Rea's work include Breast Cancer Treatment Studies (6 papers), Cancer Treatment and Pharmacology (5 papers) and Estrogen and related hormone effects (4 papers). D. Rea is often cited by papers focused on Breast Cancer Treatment Studies (6 papers), Cancer Treatment and Pharmacology (5 papers) and Estrogen and related hormone effects (4 papers). D. Rea collaborates with scholars based in United Kingdom, Netherlands and United States. D. Rea's co-authors include Jos Kleijnen, Catherine A. Forbes, A. G. H. Kessels, Mayur M. Amonkar, Rob Riemsma, Jawaher Ansari, Gerard Groenewegen, Syed A. Hussain, W.W. ten Bokkel Huinink and D. Palmer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

D. Rea

20 papers receiving 312 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
D. Rea United Kingdom	9	156	92	77	64	49	22	321
Yi–Dan Yan China	13	68 0.4×	47 0.5×	34 0.4×	111 1.7×	23 0.5×	45	401
Raffaele Conca Italy	12	233 1.5×	116 1.3×	21 0.3×	106 1.7×	72 1.5×	54	533
Norman Williams United Kingdom	4	245 1.6×	74 0.8×	179 2.3×	62 1.0×	245 5.0×	6	383
Vidar G. Flote Norway	11	186 1.2×	83 0.9×	46 0.6×	104 1.6×	108 2.2×	22	385
Nasser Pouladi Iran	13	84 0.5×	19 0.2×	45 0.6×	188 2.9×	85 1.7×	50	455
Emanuela S. Milani Switzerland	6	76 0.5×	16 0.2×	20 0.3×	100 1.6×	44 0.9×	8	241
Susanne Haas Germany	14	131 0.8×	37 0.4×	64 0.8×	184 2.9×	70 1.4×	23	429
Terumi Mizuno Japan	9	83 0.5×	48 0.5×	37 0.5×	164 2.6×	55 1.1×	14	364
Aylin Köseler Türkiye	13	49 0.3×	59 0.6×	39 0.5×	114 1.8×	25 0.5×	42	499
Manuela Tamburo De Bella Italy	9	183 1.2×	60 0.7×	131 1.7×	151 2.4×	96 2.0×	16	370

Countries citing papers authored by D. Rea

Since Specialization

Citations

This map shows the geographic impact of D. Rea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Rea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Rea more than expected).

Fields of papers citing papers by D. Rea

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Rea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Rea. The network helps show where D. Rea may publish in the future.

Co-authorship network of co-authors of D. Rea

This figure shows the co-authorship network connecting the top 25 collaborators of D. Rea. A scholar is included among the top collaborators of D. Rea based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Rea. D. Rea is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ratnasingham, Sujeevan, Catherine Wei, D. Susan Willis Chan, et al.. (2024). BOLD v4: A Centralized Bioinformatics Platform for DNA-Based Biodiversity Data. Methods in molecular biology. 2744. 403–441. 33 indexed citations

Stevens, Andrew, et al.. (2024). Real-world Data on Safety Outcome with Treatment of Adjuvant Abemaciclib plus Endocrine Therapy in High-risk Early Hormone-positive, HER2-negative Breast Cancer Patients. Clinical Oncology. 36(4). e110–e111. 1 indexed citations

Paillassa, Jérôme, Roberta Di Blasi, Sophie Bernard, et al.. (2019). PS1219 CAUSES OF NON – ELIGIBILITY FOR CD19 CAR T‐CELL IMMUNOTHERAPY IN PATIENTS WITH RELAPSE/REFRACTORY DLBCL. EXPERIENCE OF SAINT‐LOUIS HOSPITAL. HemaSphere. 3(S1). 556–556. 1 indexed citations

Thomas, James, AM Hanby, Sarah E. Pinder, et al.. (2017). Abstract P3-17-06: LORIS trial of active monitoring for DCIS: How does the online pathology eligibility review process work?. Cancer Research. 77(4_Supplement). P3–17. 3 indexed citations

Drew, Yvette, JA Ledermann, Geoff Hall, et al.. (2016). Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer (vol 114, pg 723, 2016). 1 indexed citations

Stein, Robert C., Luke Hughes‐Davies, J. M. S. Bartlett, et al.. (2015). 1809 Results of the OPTIMA (Optimal Personalized Treatment of early breast cancer usIng Multi-parameter Analysis) prelim study. European Journal of Cancer. 51. S268–S268. 2 indexed citations

Riemsma, Rob, Catherine A. Forbes, A. G. H. Kessels, et al.. (2010). Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. Breast Cancer Research and Treatment. 123(1). 9–24. 63 indexed citations

Bartlett, JMS, CJH van de Velde, Annette Hasenburg, et al.. (2010). Abstract P3-10-33: Mammostrat® as an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in Postmenopausal Early Breast Cancer: Preliminary Data of the TEAM Pathology Study. Cancer Research. 70(24_Supplement). P3–10. 1 indexed citations

Hille, E.T.M., Annette Hasenburg, D. Rea, et al.. (2010). Abstract S2-3: The Impact of Body Mass Index (BMI) on the Efficacy of Adjuvant Endocrine Therapy in Postmenopausal Hormone Sensitive Breast Cancer (BC) Patients; Exploratory Analysis from the TEAM Study. Cancer Research. 70(24_Supplement). S2–3. 16 indexed citations

10.

Ansari, Jawaher, D. Palmer, D. Rea, & Syed A. Hussain. (2009). Role of Tyrosine Kinase Inhibitors in Lung Cancer. Anti-Cancer Agents in Medicinal Chemistry. 9(5). 569–575. 25 indexed citations

11.

Campbell, Helen, David Epstein, S M Griffin, et al.. (2009). Modelling the cost-effectiveness of first, second and third generation polychemotherapy regimens in women with early breast cancer who have differing prognoses.. Cancer Research. 69(2_Supplement). 6106–6106.

12.

Waring, R. H., Stephen D. Ayers, A. Gescher, et al.. (2007). Phytoestrogens and xenoestrogens: The contribution of diet and environment to endocrine disruption. The Journal of Steroid Biochemistry and Molecular Biology. 108(3-5). 213–220. 38 indexed citations

13.

Rea, D., J. W. R. Nortier, W.W. ten Bokkel Huinink, et al.. (2005). A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Annals of Oncology. 16(7). 1123–1132. 69 indexed citations

14.

Young, Annie, Gulnaz Begum, Lucinda Billingham, et al.. (2005). WARP - A multicentre prospective randomised controlled trial (RCT) of thrombosis prophylaxis with warfarin in cancer patients with central venous catheters (CVCs). Journal of Clinical Oncology. 23(16_suppl). LBA8004–LBA8004. 21 indexed citations

15.

Léonard, Renaud, A. U. Buzdar, Peter Canney, et al.. (2004). Trilostane, an effective signal transduction inhibitor for advanced ER+ve and ER-ve post-menopausal breast cancer. Journal of Clinical Oncology. 22(14_suppl). 540–540. 1 indexed citations

16.

Rea, D., Louise Hiller, Helena Earl, et al.. (2004). Tolerability and efficacy of classical CMF (cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamide (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT). Journal of Clinical Oncology. 22(14_suppl). 595–595.

17.

Braun, Michael, F. Adab, C. R. Bradley, et al.. (2003). Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer. British Journal of Cancer. 89(7). 1155–1158. 13 indexed citations

18.

Bhide, Shree & D. Rea. (2003). Metastatic breast cancer response after Exemestane withdrawal: a case report. The Breast. 13(1). 66–68. 7 indexed citations

19.

Punt, Cornelis J. A., J.W.R. Nortier, W.W. ten Bokkel Huinink, et al.. (2003). 277 Combination of irinotecan and capecitabine as first line treatment in advanced colorectal cancer (ACC): results of a phase II multicenter trial. European Journal of Cancer Supplements. 1(5). S85–S85. 5 indexed citations

20.

Rea, D., Christopher Poole, & Richard Gray. (1998). Adjuvant tamoxifen: how long before we know how long?. BMJ. 316(7143). 1518–1518. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact